Brieflands
History
The company was first founded by Seyyed M. Miri and Seyed-M Alavian as an editorial group in a Medical Institute in 2007 to publish its medical journal. After three years of experience, the number of journals increased to 5 journals, and the company launched its first form of business as a VOF (collaboration) professional STM company in Heerlen, the Netherlands, which was called "Kowsarmedical Publishing." Respecting the publishing services (from submission to publishing), especially an in-house "Journal Management System," our journals increased to more than 60 STM journals between 2010 and 2019. Since 2022, "Brieflands" is the new brand name that acts as a "Science, Technical, Medical Publisher" that publishes more than 50 journals with the services provided by 97 expert employees in three different branches.
Business Profile
- Brieflands is a Registered Trademark with record number 1454012.
- Brieflands has been registered as a General partnership (Vennootschap onder firma) company in the Chamber of Commerce (Kamer van Koophandel) of the Netherlands since 2010.
- KvK number: 89235444.
- BTW (VAT) number: NL864918896B01 (check online at VIES)
- RSIN: 864918896
- Nedmedica is our related company which is specialized in Author Services.
- Our former branding name was Kowsarmedical Publishing (2010-2021).
Communities in Brieflands
Select a community to browse its collections.
Recent Submissions
The Tale of a Giant Calcaneal Spur Measuring 31 mm: A Rare Case Report
(Brieflands, 2025-01-31) Razieh Shahnazari; Marlena Jabra; Sina Karaji; Niloofar Alimohamadi; Shahriar Shirzadi; Razieh Shahnazari [0000-0001-6563-7035]; Sina Karaji [0000-0003-2732-7858]; Shahriar Shirzadi [0000-0002-0432-9407]
Introduction: This study presents a unique case report of a 31 mm calcaneal spur, shedding light on the complexities of heel spur formation and its consequences. The connection between spur length and pain intensity remains uncertain, while factors such as obesity, biomechanical foot disorder, combined tarsal coalition, and loading patterns are implicated in their development. Case Presentation: A 38-year-old male with chronic plantar fasciitis and persistent heel discomfort presented with a congenitally shorter affected foot. Following initial medical attention for heel pain and an unidentified injection providing temporary relief, his symptoms worsened significantly over three months, reaching a distressing level of 8/10 on the pain scale. Morning and post-rest exacerbations were noticeably mitigated by activity. An X-ray revealed a 31 × 17 mm heel spur at the plantar calcaneal tuberosity with dysplastic rounded mortise and calcaneus. MRI showed evidence of extraarticular non-osseous talocalcaneal coalitions with degenerative changes in the angle of Gissane. It is possible that the patient’s problems are due to the initial coalition and secondary heel spur and plantar fasciitis. Conclusion: This rare case of a 31 mm calcaneal spur emphasizes the diagnostic value of advanced imaging in complex heel pain. While spur size alone may not predict symptoms, associated biomechanical and structural anomalies complicate management. Non-surgical treatments remain primary, but surgical options may be necessary for resistant cases. Further studies are needed to guide treatment strategies for unusually large spurs.
The Prognostic Ability of On-Admission Hemoglobin Levels in Children with COVID-19: The PICU Experience at a Tertiary Hospital in Iran
(Brieflands, 2025-07-09) Mehrnaz Olfat; Mohammed Saad Albalaghee; Leila Seddigh; Meisam Sharifzadeh; Bahareh Yaghmaie; Seyed Abbas Hassani; Farzaneh Beirami; Zeinab Pourhadi; Mehrdad Goudarzi; Masoud Mohammadpour; Mehrnaz Olfat [0000-0003-1387-3305]; Meisam Sharifzadeh [0000-0002-0936-5941]
Background: COVID-19 can lead to hematological abnormalities, including anemia. Pre-existing anemia can exacerbate the severity of the disease by increasing the peripheral tissue demand for oxygen. Both conditions can contribute to hypoxia. Objective: We aimed to investigate the relationship between COVID-19 infection and on-admission anemia in critically ill children and assess their effects on severe outcomes. Methods: This retrospective study was conducted at Children’s Medical Center during the COVID-19 pandemic. Patients were divided into two groups based on the first hemoglobin level: Anemic and non-anemic. For statistical analysis, we used univariate and multivariate logistic regression models in SPSS and Stata software. Results: A total of 133 patients were enrolled with a mean age of 63.2 months. Fifty-eight patients had anemia for age, and 75 were non-anemic. Among the patients, 53.5% of females and 35.6% of males were anemic (P = 0.04). Additionally, 50.5% of anemic patients had significant prehospital comorbidities compared with 20% of previously healthy patients (P = 0.03). Overall, 72.9% of patients survived, and 27.1% died. Using univariate analysis, death occurred significantly more in anemic patients compared to others (OR: 2.27, 95% CI: 1.042 - 4.948, P = 0.037). A logistic regression model was used to adjust the impact of potential confounders, showing that death occurred 1.82 times more often in anemic patients versus non-anemic patients (OR: 1.77, 95% CI: 0.79 - 3.98, P = 0.162). Furthermore, 54.9% of patients needed vasoactive agents, and 42.7% underwent mechanical ventilation (MV) (P = 0.413 and 0.155, respectively). Conclusions: The mortality rate in our study was 27.1%. In the logistic regression model adjusting for comorbidity and sex, we found a small effect relationship between anemia and mortality. However, wide confidence intervals and non-significant p-values indicate the low power of the study, mostly due to the small sample size. Further prospective studies with a larger sample size are recommended to determine the exact relationship between anemia and mortality.
Effect of Oral Synbiotic Consumption on Glycemic Control and Honeymoon Phase Duration in Children with Type 1 Diabetes: A Randomized Clinical Trial
(Brieflands, 2025-08-31) Sara Nikpour; Nosrat Ghaemi; Nasrin Moazzen; Sepideh Bagheri; Samaneh Noroozi Asl; Hamid Ahanchian; Tahereh Sadeghi; Nasrin Moazzen [0000-0001-8129-671X]; Hamid Ahanchian [0000-0003-3532-7428]; Tahereh Sadeghi [0000-0002-4396-2707]
Background: The present study aimed to investigate the effects of synbiotics on glycemic control and the duration of the honeymoon phase in newly diagnosed children with type 1 diabetes mellitus (T1DM). Methods: This study is a randomized, triple-blind clinical trial conducted in Mashhad in 2023. The samples included children aged 2 to 18 years who were referred to the Endocrinology Clinic of Akbar Children’s Hospital. The patients were randomly divided into two groups: Synbiotic and placebo (60 participants in each group). The synbiotic group received capsules containing specific strains of Lactobacillus, Bifidobacterium, and Streptococcus thermophiles, while the placebo group received a placebo for six months. Blood sugar control indices, HbA1c, and lipid profiles were recorded at the beginning of the study and then at three-month intervals. The duration of the honeymoon period and the number of diabetic ketoacidosis attacks during treatment were also examined. Patients were followed up every three months for one year. Data were analyzed using SPSS version 22 software, and a 95% confidence level was considered. Results: After six months, the synbiotic group showed a significant decrease in total daily insulin dose compared to the placebo group (P = 0.000). No significant differences were observed in mean HbA1c levels between the two groups before the study and three months after synbiotic consumption (P > 0.05). However, after the six-month follow-up, the synbiotic group demonstrated a significant decrease in HbA1c levels (P = 0.039). At the end of the six months, the percentage of participants in the honeymoon phase differed significantly between the two groups, with 3.3% in the placebo group and 13.3% in the synbiotic group (P = 0.048). Conclusions: Synbiotic supplementation in children with T1DM can lead to improvements in glycemic control, including reduced insulin requirements, enhanced HbA1c levels, and a prolonged honeymoon phase. These outcomes highlight the potential of synbiotics as a supportive adjunct to standard diabetes management strategies for improving glycemic control in this population.
The Proportion of PNPLA3 rs738409 GG Homozygous in Different Populations and Its Impact on Fibrosis Progression in Biopsy-Proven NAFLD Patients: Meta-Analysis and Systematic Review
(Brieflands, 2025-12-31) Shuixian Du; Jianhong Yin; Kezhen Hu; Yongning Xin
Context: Some studies have reported that the phospholipase domain-containing protein 3 (PNPLA3) rs738409 GG homozygous genotype is associated with increased risk of liver disease severity in patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD). Given the increasing global prevalence of NAFLD and the lack of definitive treatment for non-alcoholic steatohepatitis (NASH) or a first-line therapy for NAFLD, many researchers are seeking a cure for NASH in individuals with NAFLD who have the rs738409 GG homozygous genotype. Objectives: We conducted a systematic review and meta-analysis to assess the proportion of PNPLA3 rs738409 GG homozygous individuals in different populations and its impact on fibrosis progression in biopsy-proven NAFLD patients, to support data basis for Precision Gene Therapy of NAFLD. Methods: PubMed, Cochrane Library, and Embase Database were searched for case-control studies from inception to July 3, 2024. The following keywords were used: Fatty liver, PNPLA3, and rs738409 gene or variants or polymorphism or alleles. A meta-analysis and systematic review were conducted utilizing the articles retrieved. Results: A total of 13 eligible studies and 3823 people were included in this study. The pooled PNPLA3 rs738409 GG homozygous proportion of NAFLD was estimated to be 30% (95% CI: 0.22 - 0.37) in adults, 24% (95% CI: 0.15 - 0.33) in adolescents, 33% (95% CI: 0.26 - 0.39) in the Asian population, 39% (95% CI: 0.32 - 0.47) in Japanese, and 25% (95% CI: 0.22 - 0.28) in Chinese. Advanced fibrosis (≥ 2) was estimated to be 11% (95% CI: 0.07 - 0.16) in adults, 11% (95% CI: 0.06 - 0.16) in the Asian population, and 15% (95% CI: 0.07 - 0.23) in Japanese. Two articles from the Chinese population showed that advanced fibrosis (≥ 2) was estimated to be 5.9% and 4.8%. Our results showed that the incidence of GG homozygous in patients with advanced fibrosis (≥ 2) had a 1.27-fold and 1.24-fold greater proportion compared with low-level fibrosis (< 2) in adult and Asian populations, respectively. Conclusions: The rs738409 GG homozygous proportion in biopsy-proven NAFLD varies due to geographic and population heterogeneity. Our results showed that rs738409 GG homozygous exerts a strong influence on developing fibrosis.
Non-alcoholic Fatty Liver in Patients with Gallstones Undergoing Cholecystectomy
(Brieflands, 2025-12-31) Mehdi Hashemi; Samaneh Adineh; Yousef Paridar; Aziz Kassani; Mehdi Hashemi [0000-0001-7174-3651]; Samaneh Adineh [0000-0002-7943-2820]; Yousef Paridar [0000-0001-9727-4048]; Aziz Kassani [0000-0001-5188-5249]
Background: Non-alcoholic fatty liver disease (NAFLD) is a prevalent condition often associated with metabolic syndrome and gallstone disease (GSD). Objectives: The present study aimed to investigate symptomatic gallstone patients undergoing cholecystectomy. Methods: This cross-sectional study included 330 patients who underwent cholecystectomy at the Referral Hospital of Ganjavian in Dezful city, Iran, between 2020 and 2022. Patients were selected using simple random sampling. Inclusion criteria were patients aged 18 - 85 with symptomatic gallstones (GS), while exclusion criteria comprised other liver diseases. Data on age, gender, NAFLD (assessed by ultrasonography), liver enzymes, and comorbidities were collected. Results: Among the 330 patients, 31.82% (n = 105) were diagnosed with NAFLD. The mean age of the patients was 48.64 ± 13.48 years. The NAFLD was significantly associated with diabetes (OR = 2.97, 95% CI: 1.61 - 5.45), dyslipidemia (OR = 1.96, 95% CI: 1.13 - 3.37), and hypertension (OR = 2.12, 95% CI: 1.24 - 3.61). There was a significant difference between patients with NAFLD and those without NAFLD (P < 0.05). Conclusions: This study identified a significant prevalence of NAFLD at 31.82% among symptomatic gallstone patients undergoing cholecystectomy. The incidence of NAFLD showed no correlation with gender or smoking status; however, it was strongly associated with various metabolic comorbidities. These findings highlight the necessity for a comprehensive approach to managing GSD, including early detection and targeted treatment of NAFLD and its related metabolic conditions.